<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453932</url>
  </required_header>
  <id_info>
    <org_study_id>2012ZX09104-203</org_study_id>
    <nct_id>NCT02453932</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-blind, Positive /Placebo Controlled, Parallel, Three Arms Study of Tianzhi Granule in Mild to Moderate Vascular Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongzhimen Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongzhimen Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This ongoing study aimed to evaluate the efficacy and safety of Tianzhi granule in mild to&#xD;
      moderate vascular dementia in a more reasonable design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 24-weeks, multicenter, randomized, double-blind, double- placebo, parallel&#xD;
      controlled phase III trial being carried out in 23 centers around China. The study population&#xD;
      includes mild to moderate VaD patients (planned a total of 630) aged 45-85 in both gender.&#xD;
      Participants will be randomly allocated to TZK (15g/d) and placebo identified to donepezil,&#xD;
      donepezil (5mg/d) and placebo identified to TZK, or placebo identified to TZK and placebo&#xD;
      identified to donepezil for a 24-weeks double-blind treatment period . The primary outcome&#xD;
      measure is change from baseline in the Vascular Dementia Assessment Scale-Cognitive Subscale&#xD;
      and Clinician's Interview-Based Impression of Change-Plus carer Interview. The secondary&#xD;
      outcomes are changes from baseline in the Mini-Mental State Examination, Activity of Daily&#xD;
      Living Scale, Clock Drawing Test, Trail Making Test and Neuropsychiatric Inventory. Safety is&#xD;
      being assessed by observing side effects and adverse reaction during the entire treatment&#xD;
      period. Statistical analysis will be conducted according to per-protocol population and&#xD;
      intend-to-treat population and the safety will be analyzed in safety set.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Vascular Dementia Assessment Scale-Cognitive Subscale(VADAS-cog) from baseline after 24 weeks' intervention</measure>
    <time_frame>week 0, 4, 12, 24</time_frame>
    <description>Cognition : VaDAS-cog is a revision of the ADAS-cog to be a better measure in vascular conditions. The original ADAS-cog developed by Rosen et al., measures cognitive performance by combining ratings of 11 items. The cognitive domains mainly addressed by ADAS-cog are memory (short term), language, ability to orientate (reflects memory), construction/planning of simple designs and performance. In addition to ADAS-cog, the VaDAS-cog comprises additional frontal lobe tests reflecting attention, working memory, executive function, and verbal fluency.The VADAS-cog will conducted at baseline, 4weeks, 12weeks, 24weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Clinician's Interview-Based Impression of Change-Plus carer Interview(CIBIC-plus) from baseline after 24 weeks' intervention</measure>
    <time_frame>week 0, 4, 12, 24</time_frame>
    <description>Overall clinical response: CIBIC-plus is a 7-point scale which provides an index of clinically important change for dementia patients. It is a global measure of detectable change in concentration, orientation, memory, language, behavior, initiative and activities of daily living, usually requiring separate interviews with patients and caregivers,the CIBIC-plus will be conducted at baseline, 4weeks, 12weeks, 24weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Mini-Mental State Examination(MMSE) from baseline after 24 weeks' treatment</measure>
    <time_frame>week 0, 4, 12, 24</time_frame>
    <description>Global cognition will be assessed by the MMSE,which will be conducted at baseline, 4weeks, 12weeks, 24weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Activity of Daily Living Scale(ADL) from baseline after 24 week's intervention</measure>
    <time_frame>week 0, 4, 12, 24</time_frame>
    <description>Function:The ADL mainly used to measure the basic activities of daily living (or self-care) and the instrumental activities of daily living. The ADL scale can be divided to Physical Self-Maintenance Scale (PSMS) and the instrumental activities of daily living (IADL). The PSMS relate to physical activities, such as toileting, mobility, dressing and bathing , and the IADL contains 8 items ,such as shopping, cooking, doing laundry, handling finances, using telephone, mode of transportation, responsibility for own medication and housekeeping.The ADL wil be conducted baseline, 4weeks, 12weeks, 24weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Clock Drawing Test(CDT) from baseline after 24 week's intervention</measure>
    <time_frame>week 0, 4, 12, 24</time_frame>
    <description>Executive function and Visuospatial function : the CDT scale will be conducted at baseline, 4weeks, 12weeks, 24weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Trail Making Test (TMT) from baseline after 24 week's intervention</measure>
    <time_frame>week 0, 4, 12, 24</time_frame>
    <description>Executive function: The TMT scale will be conducted at baseline, 4weeks, 12weeks, 24weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Neuropsychiatric Inventory(NPI) from baseline after 24 weeks' intervention</measure>
    <time_frame>week 0, 4, 12, 24</time_frame>
    <description>Changes in psychological symptom: NPI is used throughout the study to assess changes in psychological symptom,the NPI will be conducted at baseline, 4 weeks, 12 weeks, 24 weeks.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">543</enrollment>
  <condition>Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>Tianzhi granule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tianzhi granule and placebo identified to donepezil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donepezil and placebo identified to Tianzhi granule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo identified toTianzhi granule and placebo identified to donepezil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tianzhi granule and placebo identified to donepezil</intervention_name>
    <description>1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks</description>
    <arm_group_label>Tianzhi granule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil and placebo identified to Tianzhi granule</intervention_name>
    <description>donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks</description>
    <arm_group_label>Donepezil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inpatients and outpatients meeting the diagnostic criteria probable VaD established&#xD;
             according to the Diagnostic and Statistical Manual of Mental Disorders (fourth&#xD;
             edition) （DSM-Ⅳ） and the National Institute of Neurological Disorders and Stroke and&#xD;
             the Association Internationale pour la Recherche et l'Enseignement en Neurosciences&#xD;
             (NINDS-AIREN)were eligible to participate,&#xD;
&#xD;
          -  diagnosis of mild to moderate vascular dementia;&#xD;
&#xD;
          -  Chinese-speaking patients aged ≥45 and≤85 years old in both gender;&#xD;
&#xD;
          -  weighing between 45 and 90kg;&#xD;
&#xD;
          -  fully conscious;&#xD;
&#xD;
          -  MMSE score of≤26 and ≥14;&#xD;
&#xD;
          -  HIS score of ≥7;&#xD;
&#xD;
          -  adequate vision and hearing ability to complete all study tests;&#xD;
&#xD;
          -  with a stable caregiver.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from the enrollment if they meet any of the followings:&#xD;
&#xD;
          -  a medical history of other dementia types, like Alzheimer's disease, Parkinson's&#xD;
             disease dementia, Huntington disease, Normal pressure hydrocephalus, et al;&#xD;
&#xD;
          -  major depression (HAMD for 17 items&gt;17) or psychotic disorder;&#xD;
&#xD;
          -  acute stage of cerebral hemorrhage or subarachnoid hemorrhage;&#xD;
&#xD;
          -  hypothyroidism;&#xD;
&#xD;
          -  drug or alcohol abuse;&#xD;
&#xD;
          -  epilepsy history; myasthenia gravis history;&#xD;
&#xD;
          -  severe cardiovascular disease(severe arrhythmia with heart rate≥100 or≤60 times per&#xD;
             min, left bundle branch block, myocardial infarction within 3 months, systolic&#xD;
             pressure≥180mmHg or ≤90mmHg);&#xD;
&#xD;
          -  severe liver or kidney dysfunction (alanine aminotransferase&gt;60 IU/L, aspartate&#xD;
             transaminase&gt;60 IU/L or serum creatinine &gt;266μmol/L);&#xD;
&#xD;
          -  severe asthma or chronic obstructive pulmonary disease;&#xD;
&#xD;
          -  gastrointestinal tract obstruction or severe peptic ulcer; glaucoma;&#xD;
&#xD;
          -  administration of cholinesterase inhibitors, memantine or nimodipine in the last&#xD;
             month;&#xD;
&#xD;
          -  use of sympathomimetic agent, antihistamine drug, antianxiety drugs or tranquilizer&#xD;
             within 48h before assessment;&#xD;
&#xD;
          -  use of antipsychotic drugs within 72h before assessment;&#xD;
&#xD;
          -  participation in other clinical trials; allergic history to any type of medication&#xD;
             used in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinzhou Tian, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongzhimen Hospital, Beijing University of Chinese Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dongzhimen Hospital,Beijing University of Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>January 5, 2020</last_update_submitted>
  <last_update_submitted_qc>January 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dongzhimen Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Jinzhou Tian</investigator_full_name>
    <investigator_title>MD，PhD</investigator_title>
  </responsible_party>
  <keyword>Vascular dementia</keyword>
  <keyword>Tianzhi granule</keyword>
  <keyword>Herbal medicine</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Three arms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

